Abnormal localization of iron regulatory protein in Alzheimer's disease

Brain Research

Volumn 788, Issue 1-2, 1998, Pages 232-236

  Smith, Mark A ^a   Wehr, Kristina ^b   Harris, Peggy L R ^a   Siedlak, Sandra L ^a   Connor, James R ^c   Perry, George ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Iron; Metabolism; Oxidative stress

Indexed keywords

IRON; IRON REGULATORY FACTOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IRON METABOLISM; NEURITE; NEUROFIBRILLARY TANGLE; NEUROPIL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; IMMUNOHISTOCHEMISTRY; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; IRON-REGULATORY PROTEINS; IRON-SULFUR PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RNA-BINDING PROTEINS;

EID: 0032579795     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00002-X     Document Type: Article

References (39)

1. Butt J., Kim H.Y., Basilion J.P., Cohen S., Iwai K., Philpott C.C., Altschul S., Klausner R.D., Rouault T.A. Differences in the RNA binding sites of iron regulatory proteins and potential target diversity. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4345-4349.
2. Connor J.R., Menzies S.L., St. Martin S.M., Mufson E.J. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 31:1992;75-83.
3. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31:1992;327-335.
4. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, Parkinsonian and Alzheimer's diseased brains. J. Neurochem. 65:1995;717-724.
5. Crapper McLachlan D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 337:1991;1304-1308.
6. Finch C.E., Cohen D.M. Aging, metabolism, and Alzheimer disease: review and hypotheses. Exp. Neurol. 143:1997;82-102.
7. Good P.F., Perl D.P., Bierer L.M., Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann. Neurol. 31:1992;286-292.
8. Gray N.K., Hentze M.W. Iron regulatory protein prevents binding of the 43S translation pre-initiation complex to ferritin and eALAS mRNAs. EMBO J. 13:1994;3882-3891.
9. Henderson B.R., Menotti E., Kuhn L.C. Iron regulatory proteins 1 and 2 bind distinct sets of RNA target sequences. J. Biol. Chem. 271:1996;4900-4908.
10. Hentze M.W., Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 93:1996;8175-8182.
11. Hu J., Connor J.R. Demonstration and characterization of the iron regulatory protein in human brain. J. Neurochem. 67:1996;838-844.
12. Iwai K., Klausner R.D., Rouault T.A. Requirements for iron-regulated degradation of the RNA binding protein, iron regulatory protein 2. EMBO J. 14:1995;5350-5357.
13. Kim H.Y., Klausner R.D., Rouault T.A. Translational repressor activity is equivalent and is quantitatively predicted by in vitro RNA binding for two iron-responsive element-binding proteins, IRP1 and IRP2. J. Biol. Chem. 270:1994;4983-4986.
14. Klausner R.D., Rouault T.A., Harford J.B. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell. 72:1993;19-28.
15. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., LeWitt P.A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65:1995;710-724.
16. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD): II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
17. Mori H., Kondo J., Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science. 235:1987;1641-1644.
18. Pantopoulos K., Gray N.K., Hentze M.W. Differential regulation of two related RNA-binding proteins, iron regulatory protein (IRP) and IRPB. RNA. 1:1995;155-163.
19. 2) control mammalian iron metabolism by different pathways. Mol. Cell. Biol. 16:1996;3781-3788.
20. Pappolla M.A., Omar R.A., Kim K.S., Robakis N.K. Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am. J. Pathol. 140:1992;621-628.
21. Perry G., Friedman R., Shaw G., Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U.S.A. 84:1987;3033-3036.
22. Perry G., Kawai M., Tabaton M., Onorato M., Mulvihill P., Richey P., Morandi A., Connolly J.A., Gambetti P. Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. J. Neurosci. 11:1991;1748-1755.
23. Rouault T.A., Tang C.K., Kaptain S., Burgess W.H., Haile D.J., Samaniego F., McBride O.W., Harford J.B., Klausner R.D. Cloning of the cDNA encoding an RNA regulatory protein - the human iron-responsive element-binding protein. Proc. Natl. Acad. Sci. U.S.A. 87:1990;7958-7962.
24. Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68:1997;2092-2097.
25. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271:1996;18295-18298.
26. Smith M.A., Perry G. Alzheimer disease: an imbalance of proteolytic regulation? Med. Hypotheses. 42:1994;277-279.
27. Smith M.A., Kutty R.K., Richey P.L., Yan S.-D., Stern D., Chader G.J., Wiggert B., Petersen R.B., Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145:1994;42-47.
28. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.-D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. U.S.A. 91:1994;5710-5714.
29. Smith M.A., Rudnicka-Nawrot M., Richey P.L., Praprotnik D., Mulvihill P., Miller C.A., Sayre L.M., Perry G. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J. Neurochem. 64:1995;2660-2666.
30. Smith M.A., Sayre L.M., Monnier V.M., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18:1995;172-176.
31. Smith M.A., Sayre L., Perry G. Is Alzheimer's a disease of oxidative stress? Alzheimer Dis. Rev. 1:1996;63-67.
32. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature. 382:1996;120-121.
33. Smith M.A., Harris P.L.R., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:1997;2653-2657.
34. Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U.S.A. 94:1997;9866-9868.
35. L.A. Sternberger (Ed.), Immunocytochemistry, Wiley, New York, 1986.
36. Tanzi R.E., Hyman B.T. Alzheimer's mutation. Nature. 350:1991;564.
37. Theil E.C. Iron regulatory elements (IREs): a family of mRNA non-coding sequences. Biochem. J. 304:1994;1-11.
38. Thompson C.M., Markesbery W.R., Ehmann W.D., Mao Y.-X., Vance D.E. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology. 9:1988;1-7.
39. Yan S.D., Yan S.F., Chen X., Fu J., Chen M., Kuppusamy P., Smith M.A., Perry G., Godman G.C., Nawroth P., Zweier J.L., Stern D. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med. 1:1995;693-699.